ArticleFrontiers in oncology2026
Case report: Carcinoma en cuirasse-widespread cutaneous metastases from breast adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: Cutaneous metastatic carcinoma is a malignant tumor that originates outside the skin. Studies have found that the most common primary tumor in female patients with cutaneous metastatic carcinoma is breast cancer. Cutaneous metastatic carcinoma spreads to the adjacent skin through blood vessels, lymphatics, or interstitial spaces. It forms ulcerative or nodular lesions. Carcinoma en cuirasse is characterized by extensive induration and sclerosis of the skin, resembling armor, and is a rare form of cutaneous metastatic carcinoma. Patient concerns: We report a rare case of a 59-year-old patient who developed dark red nodules on the skin of the breast in 2013. These nodules gradually enlarged, ultimately causing the breast to lose its normal shape. Subsequently, the skin on the chest and back thickened, accompanied by local erosion and ulceration that gave the skin a hardened, armor-like appearance. Diagnoses: Ultrasound and chest CT suggest diffuse infiltration in the subcutaneous fat of the neck and thorax. Core-needle biopsy pathology reveals infiltrating micropapillary carcinoma, with tumor invasion of the dermis, the tumor clearly originates from the breast. Interventions: The first-line treatment for advanced-stage breast cancer is the combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6 inhibitors) and aromatase inhibitors (AIs), specifically Abemaciclib and Anastrozole. Outcomes: The patient has been treated for 44 months, and the disease has significantly improved. This is evidenced by the absence of tumor tissue in the biopsy of the affected skin. Lessons: Breast cancer cutaneous metastasis, although rare, requires high vigilance, especially in the HER2-negative Luminal B subtype. The efficacy data on CDK4/6 inhibitors combined with endocrine therapy as a standard regimen for cutaneous metastasis is still lacking. It is necessary to enhance mechanistic studies and clinical observations, taking molecular characteristics into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.